Genomic Health Expanding Sales Force by 20 Percent; Starts Prostate Dx Studies | GenomeWeb

By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – Genomic Health officials today said that the firm has started the process of expanding its sales force by around 20 percent to help support the recent launch of its Oncotype DX DCIS Score test.

Speaking at the 30th Annual JP Morgan Healthcare Conference today, Genomic Health CEO Kim Popovits outlined the firm's efforts to expand the customer base for its Oncotype DX tests and announced that the company has launched a clinical validation study of its prostate cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.